This compound is a key intermediate in the pharmaceutical industry for the synthesis of proton pump inhibitors (PPIs), which are widely used to treat gastrointestinal disorders such as acid reflux, peptic ulcers, and gastroesophageal reflux disease (GERD). Its structure includes a benzimidazole core, sulfinyl group, difluoromethoxy substituent, and a 3,4-dimethoxypyridine 1-oxide moiety, making it essential in the production of PPIs that inhibit the H+/K+ ATPase enzyme to reduce stomach acid production. These structural features contribute to the stability and efficacy of the final drug formulations. It is also employed in research and development for novel acid-related therapeutic agents.